newsfilter
← Latest News
GlobeNewswire·

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged